Press-release for stocks related to als

Prices are updated after-hours

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
Published: 2022-09-21 (Crawled : 22:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M

| 1.33% | O: -0.93% H: 2.12% C: 1.58%
genetic als benefits

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Published: 2022-09-21 (Crawled : 13:00) - prnewswire.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -28.34% | O: 5.88% H: 0.0% C: -2.53%
als therapeutics

NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial
Published: 2022-09-20 (Crawled : 13:00) - prnewswire.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -30.93% | O: 1.03% H: 0.0% C: -4.59%
primec als trial positive

| -31.98% | O: 1.02% H: 2.97% C: -2.51%
primec als publication sclerosis study

| -93.65% | O: -0.95% H: 5.8% C: 3.24%
als trial

Global Roundup: Clover Progresses Universal COVID-19 Booster, TikoMed Proves Platform in ALS
Published: 2022-09-01 (Crawled : 12:20) - biospace.com/
IMMP | $2.59 3.19% 3.09% 1.4M

| 28.22% | O: 0.0% H: 0.0% C: -7.43%
BWAY | $5.03 1.93% 1.89% 26K

| 18.49% | O: -1.06% H: 0.0% C: -3.81%
AEZS | $1.97 0.73% 6K

| -54.8% | O: 0.87% H: 2.16% C: -3.9%
covid-19 global clover als universal platform

| 55.98% | O: 1.8% H: 9.01% C: 7.13%
trials als

| -92.97% | O: 1.35% H: 4.39% C: -5.53%
amx0035 treatment fda drug als application review

Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
Published: 2022-07-29 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

| -92.85% | O: 0.87% H: 2.37% C: 1.73%
treatment canada als

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML
Published: 2022-07-28 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -32.66% | O: 1.01% H: 0.0% C: -2.49%
als therapeutics biomarkers

| 10.78% | O: 1.96% H: 0.2% C: -2.61%
fda drug genetic als application grants review

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Published: 2022-07-26 (Crawled : 12:00) - globenewswire.com
IONS | $42.455 1.47% 1.45% 730K

| 10.78% | O: 1.96% H: 0.2% C: -2.61%
BIIB | $201.91 4.52% 4.32% 3.3M

| -2.69% | O: -0.42% H: 3.54% C: 2.01%
fda drug genetic als application grants review

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
Published: 2022-07-19 (Crawled : 11:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -92.96% | O: -3.52% H: 4.29% C: 0.43%
au8 treatment designation drug ema als positive cnm-au8

| -66.54% | O: 2.67% H: 2.13% C: -6.11%
sls-005 label australia als therapeutics update sclerosis study platform

Clene's ALS Drug Increases Survival by 70% in Mid-stage Study
Published: 2022-07-14 (Crawled : 17:00) - biospace.com/
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -88.19% | O: 7.64% H: 38.71% C: 33.23%
drug als study

$350M Funding Breaths New Life into Former ALS Compound for Asthma
Published: 2022-07-12 (Crawled : 15:20) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M